Company Overview
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.35.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +244.14% |
| 6 Months: | +120.47% |
| 3 Months: | -1.32% |
| 1 Month: | +29.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 41.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRVS Corvus Pharmaceuticals, Inc. R2K | 14.97 | -27.22 | $1.26B | 0.00% | -69.60% | -30.46% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.33M | -3.12M | - | -6.43M | -8.82M | -10.48M | - | -16.22M | -15.17M | -12.94M | - | -14.64M | -12.26M | -11.15M | - | -12.30M | -13.60M | -11.51M | - | -13.27M | -10.77M | -9.85M | - | -11.48M | -11.29M | -9.05M | - | -7.41M | -7.01M | -12.47M | -6.57M | -5.62M | -5.56M | -6.25M | -5.93M | -7.25M | -9.92M | -10.26M | -10.57M | -14.88M |
| Net Income | -20.23M | -3.15M | -6.04M | -6.35M | -8.64M | -10.30M | -11.09M | -16.04M | -14.98M | -12.72M | -11.93M | -14.30M | -11.63M | -10.50M | -10.51M | -11.64M | -12.98M | -11.00M | -11.05M | -12.94M | -10.61M | -9.80M | 27.35M | -11.58M | -11.75M | -10.67M | - | -8.30M | -8.36M | -14.83M | -7.87M | -6.50M | -6.00M | -5.70M | -4.26M | -40.22M | 15.19M | -8.00M | -10.16M | -13.69M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.44 | -0.36 | -0.33 | 0.92 | - | - | - | - | -0.34 | -0.28 | -0.24 | -0.20 | -0.18 | -0.18 | -0.32 | -0.17 | -0.14 | -0.12 | -0.12 | -0.07 | -0.60 | -0.13 | -0.10 | -0.12 | -0.15 |
| R&D Expense | 2.00M | 2.51M | - | 5.40M | 7.12M | 7.71M | - | 13.50M | 12.39M | 10.73M | - | 12.10M | 9.71M | 8.37M | - | 9.42M | 10.64M | 9.00M | - | 10.16M | 7.86M | 6.62M | - | 8.23M | 9.11M | 6.99M | - | 5.10M | 4.92M | 10.37M | 4.59M | 3.97M | 3.96M | 4.08M | 4.11M | 5.22M | 7.45M | 7.87M | 8.45M | 11.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -161.00K | -13.77M | -36.98M | -56.52M | -49.22M | -48.85M | -43.76M | -38.63M | -32.56M | -23.41M | -27.55M | -42.97M |
| Net Income | -161.00K | -31.34M | -36.38M | -55.66M | -46.94M | -46.67M | -6.00M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M |
| Diluted EPS | - | - | - | - | - | -1.59 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.53 |
| R&D Expense | 38.00K | 11.35M | 29.36M | 46.30M | 38.59M | 37.98M | 31.83M | 29.11M | 24.47M | 16.53M | 19.39M | 33.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 98.46M | 140.15M | 94.78M | 118.23M | 83.65M | 85.53M | 109.45M | 68.24M | 45.55M | 68.91M | 71.12M |
| Total Equity | -159.00K | -31.10M | 132.80M | 84.83M | 110.34M | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M | 32.57M | 61.20M |
| Cash & Equivalents | 12.52M | 4.11M | 5.05M | 45.11M | 39.20M | 5.15M | 16.45M | 63.46M | 13.16M | 12.62M | 8.74M | 4.58M |
| Total Liabilities | - | 3.78M | 7.35M | 9.94M | 7.90M | 12.54M | 13.38M | 12.29M | 12.12M | 6.87M | 36.34M | 9.91M |
| Current Liabilities | - | 3.07M | 5.94M | 8.97M | 7.03M | 10.22M | 12.15M | 9.69M | 10.75M | 6.87M | 35.40M | 9.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.33M | -27.86M | -46.21M | -40.99M | -37.32M | -34.78M | -36.72M | -27.02M | -23.93M | -25.42M | -32.80M |
| Investing Cash Flow | -92.03M | -42.56M | 84.83M | -30.19M | 3.25M | 44.77M | 21.56M | -23.28M | 15.54M | -27.48M | -7.80M |
| Financing Cash Flow | 94.95M | 71.36M | 1.44M | 65.27M | 24.00K | 1.31M | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Capital Expenditure | -1.75M | -2.20M | -266.00K | -355.00K | -25.00K | -76.00K | -5.00K | -269.00K | -34.00K | - | -174.00K |
| Free Cash Flow | -13.07M | -30.06M | -46.48M | -41.34M | -37.35M | -34.85M | -36.72M | -27.29M | -23.97M | - | -32.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 101.3% | 100.8% | -27.4% | -65.6% | -42.5% | -65.6% | -8.3% | -44.5% | -73.6% | -69.9% | -191.3% | -25.0% |
| ROCE % | - | -14.4% | -27.6% | -65.9% | -44.3% | -66.5% | -59.6% | -38.7% | -56.6% | -60.5% | -82.2% | -69.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 8.52% | 7.17M | $111.49M |
| 2 | Blackrock Inc. | 7.33% | 6.16M | $95.86M |
| 3 | State Street Corporation | 4.24% | 3.57M | $55.49M |
| 4 | Adams Street Partners, LLC | 3.90% | 3.28M | $50.97M |
| 5 | Vanguard Capital Management LLC | 3.85% | 3.23M | $50.33M |
| 6 | Price (T.Rowe) Associates Inc | 3.47% | 2.92M | $45.39M |
| 7 | Vivo Capital, LLC | 3.34% | 2.81M | $43.66M |
| 8 | Morgan Stanley | 2.97% | 2.50M | $38.88M |
| 9 | Deep Track Capital, Lp | 2.96% | 2.49M | $38.77M |
| 10 | Wellington Management Group, LLP | 2.76% | 2.32M | $36.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRVS
CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5HUFA4RDZTekxQekN6N1k5aTc3VDlNekN5TExDblpFRUFSX2R1NEFzX1ZMTUhramZTdTFRY044Qjh4TDFoazctRDR6Tkd1Y1FacHZYdWVBa2FJdXc?oc=5" target="_blank">CRVS News | CORVUS PHARMACEUTICALS INC (NASD…
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPSUIyQVl4SmliNjRUUWc1MEYyclhQTFBqcWFJZlptV1Z4d01sSUtHZmgxMWNFNXd4dTN2V0t6eGR0ZndQeEh4QXE4UnVrWFlFRGZ2aEdKekwzOTlxQ0VTeE5NcnlvR0phZ1I2dl8tTnlfcFhtbWhIUVlyOFlTRmM1QTlOSXJyay1VWGhvOV…
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPcDV0azZYLXRMTVRWM2VnclJCR3BMbVZWS2R2d3ZSNE5IM29mZkJIMEVQOEZZYXVIVm5xMTBrZGtFMUU5QVhCakYzOXc1c3BZWHY4aF9UVkNDNzV3NnlWMW1hR0czOWZpRFdQUWZDMXhnLUxBUndtLWJhX3FzMEJCRkZDOTRmd3F5MDQ5Vm…
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQUldobEtpNmx4NVdRMXdoX1ZNR3lkZXdQVFJVMmY0bllOTjBvbnpNeElHSzFRTW9fNVJKVWVSTFpYcUkyRWV4bk1qLTY0TVdXbkp4WERqSGtwdGtCT0Jqc2llMGsxS2tiVmMtTHpIaHZ4Z1ZfNDBXQ2VnWGV0ZGU1ejBUWlIySmhkVVlJbz…
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQTjNobXFfdHZQaC1BMElXcGhNVVFsaVhEWHNPb0RDZjI4dnpqYUhVNzZPem1XQnlvYnh1YmVtU1FIaFBCVGRxaXpuYzZrVDNWZjVteW9fM2xQUnlWcThkOHZGcnEzZm9OSGdtWWxXeEFOaENzcW9ocjhReFFaVU44RTZndHZCWk13S1FPcG…
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNQTJlYmxwUk1rUXJ5QUdHV3lMSlJMR1k3ZkJ1WHd5U0M3TnhsVlUwVW5aWExubEJEdU03RHB0a1NTN19FV1ltUDhEUE1oc3Y3R002UXNFcmR1SkhEc3IwSm5WM0RjRFpUZk5yS1Zra1g5SWdJT1VpeHVSUFhDMEhvOHA2eEpBd0FFWUNxQW…
CRVS — Frequently Asked Questions
What is the current share price of Corvus Pharmaceuticals, Inc. (CRVS)?
As of 2026-07-14 21:23 PDT, Corvus Pharmaceuticals, Inc. (CRVS) trades at $14.97 on NasdaqGM. Its 52-week range is $4.10 to $25.52.
What is the market capitalisation of CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) has a market capitalisation of $1.26B on NasdaqGM.
What is the P/E ratio of CRVS?
CRVS trades at a trailing price-to-earnings (P/E) ratio of -27.22. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.17.
What is the return on equity (ROE) of CRVS?
CRVS has a return on equity (ROE) of -30.46%. Its return on capital employed (ROCE) is -69.60%.
Is CRVS a good stock to buy?
This page provides a data-driven analysis of Corvus Pharmaceuticals, Inc. (CRVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.